Pharmacologic classification: hormone
Therapeutic classification: growth hormone (GH) inhibitor
Pregnancy risk category: C
AVAILABLE FORMS
Single use syringes: 60mg, 90mg, 120 mg
INDICATIONS AND DOSAGES
Acromegaly with inadequate response to or untreatable with surgery or radiation therapy--
Adults: Initially, 90 mg subcutaneously every 4 weeks for 3 months. Adjust dosage based on GH or insulin growth factor-1 levels; range 60 to 120 mg subcutaneously every 4 weeks.
ADJUST-A-DOSE:
For patients with renal or hepatic impairment, initially, 60 mg subcutaneously every 4 weeks for 3 months. Adjust dosage after that time based on GH or insulin growth factor-1 levels.
CONTRAINDICATIONS AND CAUTIONS
No known contraindications.
Use cautiously in patients with liver or renal disease, diabetes, history of gall stones, thyroid disorders, increased risk factors for cardiovascular events, and in pregnant and breast-feeding women.
INTERACTIONS
Drug-drug.
All drugs: Risk for decreased absorption of drugs used with lanreotide because of effects on GI tract. Monitor patient response and adjust dose accordingly.
Cyclosporine: May decrease levels of cyclosporine. Cyclosporine dose may need to be increased.
ADVERSE REACTIONS
CNS: headache.
CV: bradycardia, hypertension.
GI: diarrhea, abdominal pain, flatulence, gall stone development, nausea, vomiting, constipation.
Hematologic: anemia.
Metabolic: hypoglycemia, hyperglycemia, decreased thyroid function.
Musculoskeletal: arthralgia.
Other: weight loss, injection site reactions.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
lanreotide acetate